What Happened?
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) jumped 12.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration approved its generic lanreotide injection for immediate launch.
According to a company press release, the generic lanreotide injection is a 120 mg/0.5 mL prefilled syringe referencing SOMATULINE Depot. The product received a Competitive Generic Therapy designation from the U.S. Food and Drug Administration prior to its immediate commercial launch. Amneal launched the generic injection for the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors, and carcinoid syndrome. The rollout targets an established pharmaceutical market where the reference drug, SOMATULINE Depot, generated $983 million in annual U.S. sales for the year ended July 2026.
Is now the time to buy Amneal? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Amneal’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. Moves this big are rare for Amneal and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 8.9% on the news that the company reported strong third-quarter financial results that surpassed expectations and raised its full-year forecast. The pharmaceutical company posted adjusted earnings of $0.17 per share for the quarter, beating analyst estimates. Revenue also topped forecasts, reaching $785 million, which represented a 12% increase compared to the same period in the prior year. Bolstered by these results, Amneal provided an improved outlook for the full year. The company revised its projections for net revenue to a range between $3.0 billion and $3.1 billion and lifted its forecast for adjusted earnings per share to between $0.75 and $0.80.
Amneal is up 62% since the beginning of the year, and at $20.51 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Amneal’s shares 5 years ago would now be looking at an investment worth $4,078.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
